Viewing Study NCT04878432

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:01 PM
Ignite Modification Date: 2026-06-18 @ 8:36 PM
Study NCT ID: NCT04878432
Status: TERMINATED
Last Update Posted: 2025-10-16
First Post: 2021-05-05
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Myelodysplastic Syndrome (MDS) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None sabatolimab View
None phase II View
None MBG453 View
None TIM-3 View
None decitabine View
None azacitidine View
None oral decitabine View
None INQOVI View
None myelodysplastic syndrome (MDS) View
None adult View
None MDS View